Parkinson's Disease
Conditions
Interventions
intervention group:Beifido and or Bacillus licheniformis 2 capsules tid
control group:Keep the original anti-Parkinson's disease medication
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 40-80 years old, no gender limitation; 2. Primary Parkinson's disease patients, meeting the clinical diagnostic criteria for Parkinson's disease MDS (2015); 3. Parkinson's disease motor symptoms stable 1 month before enrollment, There is no need to frequently adjust Parkinson's disease medication in the short term; 4. No intestinal probiotics or prebiotic therapy (including lactulose) was used for 2 months before enrollment, if used, a 2-month washout period should be performed; 5. No CT, MR Check the contraindications; 6. Understand and agree to follow the research protocol, agree to join the group and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Parkinson's plus syndrome and secondary Parkinson's syndrome, such as multiple system atrophy, progressive supranuclear palsy, cortical subganglion degeneration, dementia with Lewy bodies, vascular Parkinson's syndrome, post-encephalitic Parkinson's syndrome Symptoms, or any other non-primary Parkinson's disease; 2. Take any probiotics or prebiotics (including lactulose) and antibiotics within 2 months before enrollment; 3. Combined endocrine diseases, such as diabetes or fasting blood sugar exceeding normal values Upper limit, hyperthyroidism or hypothyroidism, adrenal tumor, history of pituitary dysfunction, etc.; 4. Combined with other neurological diseases, such as cognitive impairment, MMSE scale score 17, Hamilton Anxiety Scale score >14, or taking antidepressant anxiety medication); malignancy, myelopathy, epilepsy, autonomic disorders (urinary retention, incontinence, or orthostatic hypostasis) Blood pressure, blood pressure drops more than 30/15mmHg after standing upright for 5 minutes), etc.; new onset of cerebrovascular disease or sequelae of severe cerebrovascular disease within 3 months, affecting the assessor; 5. Gastrointestinal tumor, history of inflammatory bowel disease, 3 months Other acute and chronic inflammation of the gastrointestinal tract (including acute exacerbation of cholecystitis); 6. History of gastrointestinal surgery (excluding endoscopic resection of benign gastrointestinal polyps, appendicitis) or constipation caused by surgery; 7. Anus fissure, perianal abscess, irreducible prolapse, history of pelvic trauma. 8. Severe cardiovascular disease (such as congestive heart failure with cardiac function class III-IV by the American Heart Association, history of myocardial infarction within 6 months, etc.); 9. Severe liver and kidney dysfunction, alanine aminotransferase, aspartate aminotransferase , total bilirubin is higher than 1.5 times the upper limit of normal; serum creatinine is higher than 1.5 times the upper limit of normal; 10. Pregnant and lactating women or women of gestational age 40-60 years old with positive HCG; 11. Known test results Those who are allergic to drugs or related products; 12. Those who have abnormal brain routine MR imaging; 13. Those who have a history of drug abuse or alcohol dependence; 14. Those who have participated in other clinical trials within 3 months before enrollment; 15. Those who refuse to be enrolled and patients who cannot cooperate with the investigator; the investigator judges that they are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Parkinson Disease Rating Scale (UPDRS);Magnetic resonance imaging changes of brain function and metabolism; | — |
Secondary
| Measure | Time frame |
|---|---|
| RBD Questionnaire–Hong Kong;Parkinson's disease sleep scale 2;Bristol stool classification;Patient Assessment of Constipation Symptoms; | — |
Countries
China
Contacts
Public ContactHouzhen Tuo
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed